Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Completed · Phase 1

Conditions studied: B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma

In brief

The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.

Key facts

Study ID

NCT00446342

Run by

Sunesis Pharmaceuticals

People needed

21

Starts

2007-02-01

Expected to finish

2009-03-01

Last updated by the study team

2017-04-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cytologically or histologically confirmed chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or multiple myeloma (MM).
• Evidence of relapsed disease
• Measurable disease
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

You may not qualify if…

• Prior treatment with SNS-032 injection (previously known as BMS-387032)
• Pregnant or breastfeeding
• Unwilling to use an approved, effective means of contraception according to the study site's standards
• Use of therapeutic anticoagulation agents
• Prior allogeneic bone marrow transplantation
• Prior chemotherapy, monoclonal antibodies, investigational agents, or radiation therapy within 21 days before the first dose; nitrosoureas and mitomycin are not permitted for at least 42 days before the first dose.
• Prior pelvic radiation therapy or radiation to > 25% of bone marrow reserve
• Any other medical, psychological, or social condition that would contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
• Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if the patient meets all study criteria.

Where it is running

• City of Hope — Duarte, California, United States
• Stanford Cancer Center — Stanford, California, United States
• Winship Cancer Institute at Emory University — Atlanta, Georgia, United States
• Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Hackensack University Medical Center at the Cancer Center — Hackensack, New Jersey, United States
• MD Anderson Cancer Center, University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.